METUBINE IODIDE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jan 1949
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Metubine Iodide is a legacy injectable small-molecule neuromuscular blocking agent approved in 1949 by Eli Lilly. The specific mechanism of action and indications are not documented in current records, consistent with its age and market status. This product represents a historical pharmaceutical asset now in late-stage commercial decline.
LOE Approaching
Legacy product with minimal Part D visibility and modest competitive pressure (30/100); team size likely small and defensive.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Metubine Iodide offers limited career advancement opportunity; roles focus on cost containment, institutional relationships, and regulatory compliance rather than innovation or expansion. This is a legacy product suitable for experienced professionals managing end-of-life commercial strategy or operations professionals optimizing manufacturing and distribution.
Product Manager (Legacy)
Worked on METUBINE IODIDE at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.